SRRK - Scholar Rock Holding Corporation
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
SRRK price evolution
SRRK
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $104.26 | $70.21 | $110.68 | $153.78 |
| Short term investments | $178.08 | $151.04 | $140.67 | $124 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $288.19 | $228.47 | $259.81 | $287.16 |
| Long term investments | ||||
| Property, plant & equipment | $16.02 | $18.28 | $20.88 | $23.41 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $22.84 | $22.22 | $25.09 | $27.56 |
| Total investments | $178.08 | $151.04 | $140.67 | $124 |
| Total assets | $311.04 | $250.69 | $284.9 | $314.72 |
| Current liabilities | ||||
| Accounts payable | $3.46 | $1.97 | $3.04 | $3.72 |
| Deferred revenue | ||||
| Short long term debt | $8.74 | $7.2 | $7.28 | $7.64 |
| Total current liabilities | $32.74 | $26.73 | $24.27 | $26.21 |
| Long term debt | $53.08 | $56.29 | $58.13 | $59.86 |
| Total noncurrent liabilities | $53.08 | $56.29 | $58.13 | $59.86 |
| Total debt | $61.82 | $63.49 | $65.41 | $67.5 |
| Total liabilities | $85.82 | $83.02 | $82.4 | $86.07 |
| Shareholders' equity | ||||
| Retained earnings | -$676.42 | -$630.29 | -$587.94 | -$550.01 |
| Other shareholder equity | $0.09 | -$0.02 | -$0.06 | -$0.33 |
| Total shareholder equity | $225.22 | $167.66 | $202.5 | $228.65 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $104.26 | $105.77 | $215.33 | $162.86 |
| Short term investments | $178.08 | $212.09 | $40.16 | $180.67 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $288.19 | $328.02 | $265.32 | $344.4 |
| Long term investments | ||||
| Property, plant & equipment | $16.02 | $25.93 | $35.01 | $40.38 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $22.84 | $30.14 | $39.13 | $43.9 |
| Total investments | $178.08 | $212.09 | $40.16 | $180.67 |
| Total assets | $311.04 | $358.17 | $304.44 | $388.31 |
| Current liabilities | ||||
| Accounts payable | $3.46 | $3.99 | $4.43 | $3.41 |
| Deferred revenue | $33.19 | $52.01 | ||
| Short long term debt | $8.74 | $7.85 | $8.98 | $5.37 |
| Total current liabilities | $32.74 | $36.39 | $64.3 | $42.56 |
| Long term debt | $53.08 | $49.74 | $68.07 | $51.77 |
| Total noncurrent liabilities | $53.08 | $61.54 | $68.07 | $84.97 |
| Total debt | $61.82 | $69.4 | $77.06 | $57.14 |
| Total liabilities | $85.82 | $97.93 | $132.37 | $127.53 |
| Shareholders' equity | ||||
| Retained earnings | -$676.42 | -$510.63 | -$376.13 | -$244.33 |
| Other shareholder equity | $0.09 | -$0.88 | -$0.04 | -$0 |
| Total shareholder equity | $225.22 | $260.24 | $172.07 | $260.77 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $34.96 | $30.34 | $26.87 | $29.73 |
| Selling, general & administrative | $13.07 | $13.34 | $12.21 | $10.77 |
| Total operating expenses | $48.03 | $43.67 | $39.08 | $40.51 |
| Operating income | -$48.03 | -$43.67 | -$39.08 | -$40.51 |
| Income from continuing operations | ||||
| EBIT | -$46.13 | -$42.36 | -$37.92 | -$39.38 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$46.13 | -$42.36 | -$37.92 | -$39.38 |
| Income (for common shares) | -$46.13 | -$42.36 | -$37.92 | -$39.38 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $33.19 | $18.82 | $15.4 | |
| Cost of revenue | ||||
| Gross Profit | $33.19 | $18.82 | $15.4 | |
| Operating activities | ||||
| Research & development | $121.9 | $124.44 | $108.47 | $74.06 |
| Selling, general & administrative | $49.4 | $43.12 | $40.27 | $28.22 |
| Total operating expenses | $171.29 | $167.56 | $148.74 | $102.28 |
| Operating income | -$171.29 | -$134.37 | -$129.92 | -$86.88 |
| Income from continuing operations | ||||
| EBIT | -$165.79 | -$134.5 | -$131.8 | -$86.48 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$165.79 | -$134.5 | -$131.8 | -$86.48 |
| Income (for common shares) | -$165.79 | -$134.5 | -$131.8 | -$86.48 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$46.13 | -$42.36 | -$37.92 | -$39.38 |
| Operating activities | ||||
| Depreciation | $2.25 | $2.6 | $2.58 | $2.54 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.95 | $7.2 | $6.82 | $6.17 |
| Total cash flows from operations | -$37.35 | -$32.27 | -$32.55 | -$43.05 |
| Investing activities | ||||
| Capital expenditures | -$0.04 | -$0.02 | ||
| Investments | -$25.13 | -$8.47 | -$15.2 | $90 |
| Total cash flows from investing | -$25.13 | -$8.47 | -$15.24 | $89.98 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $96.53 | $0.28 | $4.69 | $1.07 |
| Net borrowings | ||||
| Total cash flows from financing | $96.53 | $0.28 | $4.69 | $1.08 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $34.05 | -$40.47 | -$43.1 | $48.01 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$165.79 | -$134.5 | -$131.8 | -$86.48 |
| Operating activities | ||||
| Depreciation | $9.97 | $9.88 | $9.02 | $3.87 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $27.14 | $27.7 | $23.15 | $11.18 |
| Total cash flows from operations | -$145.23 | -$132.69 | -$126.79 | -$60.27 |
| Investing activities | ||||
| Capital expenditures | -$0.06 | -$1.06 | -$5.25 | -$4.09 |
| Investments | $41.2 | -$170.63 | $139.56 | -$59.41 |
| Total cash flows from investing | $41.14 | -$171.7 | $134.31 | -$63.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $102.57 | $195.81 | $19.99 | $223.22 |
| Net borrowings | -$0.97 | $24.98 | $24.62 | |
| Total cash flows from financing | $102.57 | $194.83 | $44.95 | $247.82 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1.51 | -$109.56 | $52.48 | $124.05 |
News
Fundamentals
| Market cap | $1.01B |
|---|---|
| Enterprise value | $971.88M |
| Shares outstanding | 75.98M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$155.82M |
| EBIT | -$165.79M |
| Net Income | -$165.79M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | -100.00% |
| P/E ratio | -6.12 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -6.24 |
| EV/EBIT | -5.86 |
| P/S ratio | N/A |
| P/B ratio | 4.51 |
| Book/Share | 2.96 |
| Cash/Share | 1.37 |
| EPS | -$2.18 |
|---|---|
| ROA | -57.10% |
| ROE | -80.48% |
| Debt/Equity | 0.38 |
|---|---|
| Net debt/EBITDA | 0.12 |
| Current ratio | 8.80 |
| Quick ratio | 8.80 |